Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation
| Autor: | Michael J. Holman, Nasimul Ahsan, Mark V. Jarowenko, Mohammad S. Razzaque, Harold C. Yang |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Graft Rejection
Male medicine.medical_specialty Daclizumab medicine.medical_treatment Dose-Response Relationship Immunologic Antibodies Monoclonal Humanized Gastroenterology Tacrolimus Internal medicine medicine Immunology and Allergy Humans Pharmacology (medical) Renal replacement therapy Prospective Studies Kidney transplantation Transplantation business.industry Panel reactive antibody Antibodies Monoclonal Immunosuppression Receptors Interleukin-2 Middle Aged Mycophenolic Acid medicine.disease Kidney Transplantation Survival Analysis Surgery Immunoglobulin G Monoclonal Trough level Drug Therapy Combination Female business Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Zdroj: | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2(6) |
| ISSN: | 1600-6135 |
| Popis: | This study prospectively compared immunoprophylaxis with a single intraoperative dose (2 mg/kg) of monoclonal interleukin-2 receptor (IL-2R) antibody vs. noninduction in kidney transplant recipients treated with tacrolimus (FK 506), mycophenolate mofetil (MMF) and a prednisone-based immunosuppression regimen. One hundred recipients of first-kidney transplant were enrolled into the study to receive either anti-IL-2R monoclonal antibody, daclizumab (2 mg/kg intraoperatively, limited anti-IL-2R) or no induction (control). Each patient also received oral tacrolimus (dosed to target trough level 10–15 ng/mL), MMF (500 mg bid) and prednisone. The primary efficacy end-point was the incidence of biopsy proven acute rejection during the first 6 months post-transplant. The patients were also followed for 12-month graft function, and graft and patient survival rates. Other than the donor's age being significantly lower in the control group, both groups were comparable with respect to age, weight, gender, race, human leukocyte antigen (HLA)-DR mismatch, panel reactive antibody (%PRA), cold ischemic time, cytomegalovirus (CMV) status, causes of renal failure, and duration and modes of renal replacement therapy (RRT). During the first 6 months, episodes of first biopsy confirmed acute rejection was 3/50 (6%) in the limited anti-IL-2R group and 8/50 (16%) in the controls (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text